Sonoma Pharmaceuticals, Inc. (SNOA) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 1 Buy, 1 Hold.
Analysts estimate Earnings Per Share (EPS) of $-7.53 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-5.32 vs est $-7.53 (beat +29.4%). 2025: actual $-2.79 vs est $-0.67 (missed -316.4%). Analyst accuracy: 41%.
SNOA Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to Sonoma Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — SNOA
41%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$5.32
vs Est –$7.53
▲ 41.5% off
2025
Actual –$2.79
vs Est –$0.67
▼ 76.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — SNOA
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.013B
vs Est $0.013B
▲ 0.3% off
2025
Actual $0.014B
vs Est $0.015B
▼ 8.3% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
